Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With AML or MDS
NCT03286530Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Massachusetts General Hospital. Started Nov 2017; status: active, not recruiting.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03286530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03286530.